• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Emerg Infect Dis . SARS-CoV-2 Delta-Omicron Recombinant Viruses, United States

tetano

Editor, Senior Moderator
Emerg Infect Dis


. 2022 May 12;28(7).
doi: 10.3201/eid2807.220526. Online ahead of print.
SARS-CoV-2 Delta-Omicron Recombinant Viruses, United States

Kristine A Lacek, Benjamin L Rambo-Martin, Dhwani Batra, Xiao-Yu Zheng, Norman Hassell, Hitoshi Sakaguchi, Thomas Peacock, Natalie Groves, Matthew Keller, Malania M Wilson, Mili Sheth, Morgan L Davis, Mark Borroughs, Jonathan Gerhart, Samuel S Shepard, Peter W Cook, Justin Lee, David E Wentworth, John R Barnes, Rebecca Kondor, Clinton R Paden

Abstract

To detect new and changing SARS-CoV-2 variants, we investigated candidate Delta-Omicron recombinant genomes from Centers for Disease Control and Prevention national genomic surveillance. Laboratory and bioinformatic investigations identified and validated 9 genetically related SARS-CoV-2 viruses with a hybrid Delta-Omicron spike protein.

Keywords: 2019 novel coronavirus disease; COVID-19; Delta; Omicron; SARS-CoV-2; United States; bioinformatics; coronavirus disease; next-generation sequencing; recombination; respiratory infections; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.
 
Back
Top Bottom